Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Core Laboratories (CLB) EBT (2022 - 2025)

Historic EBT for Core Laboratories (CLB) over the last 4 years, with Q3 2025 value amounting to $18.3 million.

  • Core Laboratories' EBT rose 948.19% to $18.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.2 million, marking a year-over-year decrease of 304.13%. This contributed to the annual value of $46.2 million for FY2024, which is 1207.72% up from last year.
  • Per Core Laboratories' latest filing, its EBT stood at $18.3 million for Q3 2025, which was up 948.19% from $12.6 million recorded in Q2 2025.
  • Core Laboratories' EBT's 5-year high stood at $18.3 million during Q3 2025, with a 5-year trough of $1.8 million in Q1 2025.
  • In the last 4 years, Core Laboratories' EBT had a median value of $11.5 million in 2023 and averaged $10.9 million.
  • Its EBT has fluctuated over the past 5 years, first skyrocketed by 7518.17% in 2023, then crashed by 6474.36% in 2025.
  • Core Laboratories' EBT (Quarter) stood at $12.5 million in 2022, then decreased by 12.55% to $11.0 million in 2023, then grew by 5.31% to $11.5 million in 2024, then skyrocketed by 58.32% to $18.3 million in 2025.
  • Its EBT was $18.3 million in Q3 2025, compared to $12.6 million in Q2 2025 and $1.8 million in Q1 2025.